• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PAR-4激动剂AYPGKF刺激人血小板生成血栓素。

PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets.

作者信息

Henriksen Ruth Ann, Hanks Vallere K

机构信息

Department of Internal Medicine, Brody School of Medicine at East Carolina University, Greenville, NC 27858-4354, USA. henriksenr@ mail.ecu.edu

出版信息

Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):861-6. doi: 10.1161/01.atv.0000014742.56572.25.

DOI:10.1161/01.atv.0000014742.56572.25
PMID:12006403
Abstract

Previous reports have indicated that thrombin-induced thromboxane production by human platelets occurs through two types of interaction between thrombin and the platelet surface. One of these interactions is with protease activated receptor(PAR)-1, the first identified thrombin receptor. These studies were undertaken to determine whether stimulation of PAR-4 also results in thromboxane production. The results show that treatment of washed human platelets with the PAR-4 agonist AYPGKF stimulates a maximum of 40% to 60% of the thromboxane produced by 100 nmol/L thrombin. Maximal thromboxane production requires approximately 1.0 mmol/L AYPGKF, despite the observation that maximal aggregation is produced by 45 micromol/L AYPGKF. Thromboxane produced by the combined stimulation of PAR-1 and PAR-4 is additive. Pretreatment of platelets with 45 micromol/L AYPGKF partially desensitizes thromboxane production in response to higher concentrations of AYPGKF and thrombin but not to stimulation by SFLLRN. PAR-4-induced stimulation is also significantly inhibited by 60 micromol/L genistein. It is concluded that activation through either PAR-1 or PAR-4 results in thromboxane production, but that stimulation of neither receptor alone produces thromboxane equivalent to that produced by 100 nmol/L thrombin. Thus, these findings demonstrate the presence of two pathways for thrombin-induced thromboxane production by platelets as proposed previously.

摘要

先前的报道指出,凝血酶诱导人血小板产生血栓素是通过凝血酶与血小板表面的两种相互作用实现的。其中一种相互作用是与蛋白酶激活受体(PAR)-1,即首个被鉴定出的凝血酶受体。开展这些研究是为了确定PAR-4的激活是否也会导致血栓素的产生。结果显示,用PAR-4激动剂AYPGKF处理洗涤后的人血小板,所刺激产生的血栓素最多为100 nmol/L凝血酶所产生血栓素的40%至60%。尽管观察到45 μmol/L AYPGKF可产生最大聚集,但最大血栓素生成需要约1.0 mmol/L AYPGKF。PAR-1和PAR-4联合刺激所产生的血栓素具有加和性。用45 μmol/L AYPGKF预处理血小板会使血小板对更高浓度的AYPGKF和凝血酶刺激产生的血栓素生成部分脱敏,但对SFLLRN刺激不产生脱敏。PAR-4诱导的刺激也会被60 μmol/L染料木黄酮显著抑制。得出的结论是,通过PAR-1或PAR-4激活都会导致血栓素生成,但单独刺激这两种受体所产生的血栓素都不等于100 nmol/L凝血酶所产生的血栓素。因此,这些发现证明了先前提出的凝血酶诱导血小板产生血栓素存在两条途径。

相似文献

1
PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets.PAR-4激动剂AYPGKF刺激人血小板生成血栓素。
Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):861-6. doi: 10.1161/01.atv.0000014742.56572.25.
2
Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor.凝血酶诱导人血小板合成血栓素。阴离子结合别构位点I非依赖性受体的特性。
Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3519-26. doi: 10.1161/01.atv.17.12.3519.
3
The role of PAR4 in thrombin-induced thromboxane production in human platelets.PAR4在凝血酶诱导人血小板产生血栓素中的作用。
Thromb Haemost. 2003 Aug;90(2):299-308. doi: 10.1160/TH03-02-0103.
4
The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.三磷酸腺苷(ATP)门控的P2X1受体在凝血酶和肾上腺素激活经阿司匹林处理的血小板过程中起关键作用。
J Biol Chem. 2008 Jul 4;283(27):18493-504. doi: 10.1074/jbc.M800358200. Epub 2008 May 14.
5
Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.蛋白酶激活受体1和4在没有分泌的ADP时不会刺激G(i)信号通路,并且独立于G(i)信号引起人血小板聚集。
Blood. 2002 May 15;99(10):3629-36. doi: 10.1182/blood.v99.10.3629.
6
Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4.纤溶酶介导的血小板激活通过蛋白酶激活受体4的裂解而发生。
J Biol Chem. 2004 Apr 30;279(18):18434-9. doi: 10.1074/jbc.M401431200. Epub 2004 Feb 18.
7
Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin.人血小板蛋白酶激活受体-1和-4对亚纳摩尔浓度α-凝血酶的协同激活作用。
J Biol Chem. 2008 Oct 3;283(40):26886-93. doi: 10.1074/jbc.M802237200. Epub 2008 Aug 5.
8
P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.血小板中P2Y12受体介导的凝血酶诱导的血栓素A2生成增强是通过对细胞外信号调节激酶1/2(Erk1/2)激活的调控实现的。
J Thromb Haemost. 2006 Mar;4(3):638-47. doi: 10.1111/j.1538-7836.2006.01789.x.
9
Early intraplatelet signaling enhances the release of human platelet PAR-1 and -4 amino-terminal peptides in response to thrombin.早期血小板内信号传导增强了人血小板PAR-1和-4氨基末端肽对凝血酶的释放反应。
Biochemistry. 2009 Feb 24;48(7):1562-72. doi: 10.1021/bi801399c.
10
Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand.涉及人血小板蛋白酶激活受体-4通过其连接配体类似物的激活的分子要求。
Platelets. 2017 Dec;28(8):812-821. doi: 10.1080/09537104.2017.1282607. Epub 2017 Mar 7.

引用本文的文献

1
Characterization of the distinct mechanism of agonist-induced canine platelet activation.激动剂诱导犬血小板活化的不同机制的表征
J Vet Sci. 2019 Jan 31;20(1):10-15. doi: 10.4142/jvs.2019.20.1.10.
2
Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A2α Activity and Its Role in Human Platelet Activation.血小板脂质组学分析:对胞质磷脂酶A2α活性及其在人血小板活化中作用的新见解。
Biochemistry. 2015 Sep 15;54(36):5578-88. doi: 10.1021/acs.biochem.5b00549. Epub 2015 Sep 1.
3
Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
人类血小板PAR4凝血酶受体中的常见变异会改变血小板功能,且存在种族差异。
Blood. 2014 Nov 27;124(23):3450-8. doi: 10.1182/blood-2014-04-572479. Epub 2014 Oct 7.
4
Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.通过蛋白酶激活受体-4和Gq信号轴的种族依赖性血小板激活机制。
Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2644-50. doi: 10.1161/ATVBAHA.114.304249. Epub 2014 Oct 2.
5
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.急性心肌梗死管理中未满足的需求:新型蛋白酶激活受体-1拮抗剂沃拉帕沙的作用。
Vasc Health Risk Manag. 2014 Apr 3;10:177-88. doi: 10.2147/VHRM.S36045. eCollection 2014.
6
Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model.使用基于主体的模型研究血小板-肿瘤细胞相互作用在转移进展中的关键作用。
Theor Biol Med Model. 2014 Apr 12;11:17. doi: 10.1186/1742-4682-11-17.
7
Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c.人种间人血小板 PAR4 反应性的差异反映了 PCTP 和 miR-376c 的表达。
Nat Med. 2013 Dec;19(12):1609-16. doi: 10.1038/nm.3385. Epub 2013 Nov 10.
8
Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.蛋白酶激活受体(PARs)——聚焦于受体-受体相互作用及其生理和病理生理学影响。
Cell Commun Signal. 2013 Nov 11;11:86. doi: 10.1186/1478-811X-11-86.
9
Antiplatelet therapy: thrombin receptor antagonists.抗血小板治疗:凝血酶受体拮抗剂。
Br J Clin Pharmacol. 2011 Oct;72(4):658-71. doi: 10.1111/j.1365-2125.2010.03884.x.
10
Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis.血小板蛋白酶激活受体信号转导通过不同的机制激活环氧化酶-1 和 12-脂氧合酶催化的胞质型磷脂酶 A2α。
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):435-42. doi: 10.1161/ATVBAHA.110.219527. Epub 2010 Dec 2.